Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022

Saba A Qasmieh, View ORCID ProfileMcKaylee M Robertson, Chloe A Teasdale, Sarah G Kulkarni, View ORCID ProfileDenis Nash
doi: https://doi.org/10.1101/2022.04.23.22274214
Saba A Qasmieh
1Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); 55 W 125th St, 6th Floor, New York, NY 10027, USA
2Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); 55 W 125th St, New York, NY 10027, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: saba.qasmieh@sph.cuny.edu
McKaylee M Robertson
1Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); 55 W 125th St, 6th Floor, New York, NY 10027, USA
2Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); 55 W 125th St, New York, NY 10027, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for McKaylee M Robertson
Chloe A Teasdale
1Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); 55 W 125th St, 6th Floor, New York, NY 10027, USA
2Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); 55 W 125th St, New York, NY 10027, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah G Kulkarni
1Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); 55 W 125th St, 6th Floor, New York, NY 10027, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Nash
1Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); 55 W 125th St, 6th Floor, New York, NY 10027, USA
2Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); 55 W 125th St, New York, NY 10027, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Denis Nash
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.

Competing Interest Statement

Nash, Kulkarni, and Robertson have received COVID-19 research finding from Pfizer for a separate project.

Funding Statement

Funding for this project was provided by the CUNY Institute for Implementation Science in Population Health (cunyisph.org).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 27, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022
Saba A Qasmieh, McKaylee M Robertson, Chloe A Teasdale, Sarah G Kulkarni, Denis Nash
medRxiv 2022.04.23.22274214; doi: https://doi.org/10.1101/2022.04.23.22274214
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022
Saba A Qasmieh, McKaylee M Robertson, Chloe A Teasdale, Sarah G Kulkarni, Denis Nash
medRxiv 2022.04.23.22274214; doi: https://doi.org/10.1101/2022.04.23.22274214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9778)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2316)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (505)
  • Infectious Diseases (except HIV/AIDS) (11654)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2186)
  • Public and Global Health (4669)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)